GSK, Sanofi, and Takeda Partner with Singapore on Biologics Innovation

GSK, Sanofi, and Takeda announced a partnership with Singapore’s Agency for Science, Technology, and Research (A*STAR) and various Singapore universities. The goal of this partnership, formalized through the Biologics Pharma Innovation Program Singapore (BioPIPS), is to boost Singapore's biologics manufacturing capabilities, including recombinant therapeutic proteins and vaccines.

The colloborative effort will bring together the companies and Singaporean researchers to enhance manufacturing productivity, improve operational efficiency, and reach sustainability goals. It will be composed of three workstreams:

1. The "Sensing and Modeling" workstream, focused on machine learning and mechanistic workflows to enable simplified and faster workflows
2. The "Sustainability" workstream, focused on tackling sustainability challenges in biologics and vaccines manufacturing via exploration of novel materials, circular economy approaches, and models promoting more sustainable and resilient supply chains
3. The "Compliant Agility" workstream, focused on removing manual tasks to improve productivity while retaining compliance

“The objectives of BioPIPS are aligned to Takeda’s ambitions of being net carbon zero in our operations by 2035 and how we can tap on data, digital, and technology to transform our manufacturing site. We look forward to this partnership with Singapore’s research ecosystem to further strengthen our capabilities and discover new and sustainable ways to develop and manufacture innovative medicine to deliver on Takeda’s commitment to patient, people, and planet,” comments George Lam, site head, Takeda Manufacturing Singapore.

Read more about the partnership here.